Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma

In a report released today, Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company, with a price target of $40.00.

Serge Belanger’s rating is based on several compelling factors. NewAmsterdam Pharma Company has shown promising developments with its ongoing PREVAIL CVOT trial, which is expected to provide significant data in the latter half of 2026 or early 2027. The company’s strategy includes submitting a New Drug Application for obicetrapib, leveraging results from multiple trials, which could align with a potential FDA approval around the time of the PREVAIL readout.
Moreover, NewAmsterdam Pharma’s strong financial position, with approximately $783 million in cash, ensures they have the resources to sustain operations beyond the PREVAIL trial readout and into the initial phase of commercial launch. The valuation of the company appears to underestimate the unique profile and market potential of obicetrapib, particularly in the lipid-lowering therapy market, supporting the Buy rating and a price target of $40.